On Oct 13, 2016, we issued an updated research report on Thermo Fisher Scientific Inc. (TMO - Free Report) , a scientific instrument maker and world leader in serving science.
Thermo Fisher recently closed the acquisition of FEI Company, Inc., a prominent player in the field of high-performance electron microscopy. This colossal $4.2 billion takeover remains part of Thermo Fisher’s strategy of expansion through acquisitions. This buyout will enable the company to access FEI’s industry-leading high-performance electron microscopy platform used for protein study, which in turn facilitates life-science research. Following the deal closure, Thermo Fisher plans to integrate the FEI business within its Analytical Instruments segment.
We also await the integration and expected synergy from Affimetrix, the recently completed mega acquisition by Thermo Fisher. This buyout is expected to boost the company's offering in the fast-growing flow cytometry market through an advanced antibody portfolio.
In genetic analysis, Affymetrix's technologies should perfectly complement Thermo Fisher's products in the targeted clinical and applied markets. The company expects this acquisition to generate attractive financial returns, including an accretion of 10 cents to its adjusted EPS in the first full year of the deal. Total synergy value is pegged at $70 million by the third year post completion of the deal, which comprises cost synergy of $55 million and adjusted operating income benefit of $15 million.
Additionally, the Life Technologies integration is progressing well and Thermo Fisher is on track to deliver revenue and cost synergy targets from the same. By year-end 2015, the company realized $130 million of incremental cost synergies, in line with its full-year target. Revenue synergies at the end of 2015 were $90 million, much faster than anticipated. This puts Thermo Fisher in a comfortable position to achieve its full-year 2016 targeted synergy to deliver $150 million in revenue.
Thermo Fisher has carried out multiple acquisitions in the past that have added complementary technologies, expanded its presence in high-growth markets, and generated cost and revenue synergies, thereby creating shareholder value. Apart from boosting revenue accretion, these deals have historically benefited the company's operating margin while also resulting in tax synergies.
Thermo Fisher boasts strong international operations and has witnessed consistent growth in the Asia-Pacific and emerging markets. The company plans to continue strengthening its foothold in emerging markets, such as China and India, and translate this success to other high-priority opportunities in regions such as South Korea, Russia and Brazil. In the last reported second-quarter 2016, standout contributors were China, South Korea, India and Southeast Asia.
However, economic uncertainties and currency headwinds continue to act as major dampeners. Thermo Fisher currently estimates unfavorable foreign exchange to have a negative impact on its top- and bottom-line performance even in 2016, although to a lesser degree compared to 2015.
The stock currently carries a Zacks Rank #2 (Buy).
Some favorably ranked medical stocks are Boston Scientific Corporation (BSX - Free Report) , The Cooper Companies Inc. (COO - Free Report) and Laboratory Corp. of America Holdings (LH - Free Report) . All the three stocks carry a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific has gained 25.7% year to date, much better than the S&P 500’s 4.7% over the same period. Over the past three months, the company’s earnings estimates for the current year have inched up 0.9% to $1.10 per share.
Cooper has seen eight estimates move higher for the current fiscal over the past 60 days, compared to no downward movement. Accordingly, earnings estimates for the year have moved up by 1.2% to $8.42 per share. The stock recorded a gain of 33.6% year to date.
LabCorp has an impressive earnings growth rate of 11.3% for the current fiscal, ahead of the industry growth expectation of 7.6%. Year to date, the stock has performed better than the S&P 500, with a gain of 10.4%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>